A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 1633 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Actual Study Start Date: June 15, 2020
Estimated Primary Completion Date: June 28, 2024
Estimated Study Completion Date: January 31, 2025
Arms:
- Experimental: Lasmiditan High Dose
- Experimental: Lasmiditan Mid Dose
- Experimental: Lasmiditan Low Dose
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 1663 |
| Actual Study start date | 15 June 2020 |
| Estimated study completion date | 31 January 2025 |